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PROGRESSIVE SuPRANUCLEAR PALSY 
DESCRIPTION 
Progressive supranuclear palsy (PSP) is one of the 
most common parkinsonism-plus syndromes. Ack-
nowledging the seminal contributions of the three 
physicians who first described the condition (Steele, 
Richardson, & Olszweski, 1964), PSP is also referred 
to as Steele-Richardson-Olszweski syndrome. PSP 
is a rapidly progressive degenerative disease. The 
characteristic syndrome consists of supranuclear 
ophthalmoplegia, pseudobulbar palsy, and axial 
dystonia, although it may take over a year for these 
features to develop fully (Ropper & Brown, 2005). 
Early prominent features include postural 
instability, falls, executive dysfunction, and slowed 
information processing. The hallmark symptom is a 
vertical gaze palsy that is often downward but can 
sometimes occur only upward. Typical age of onset 
is in the 60s (range 45-75 years) with a median sur-
vival time of approximately 6 years from the initial 
onset of symptoms (Litvan, Agid, et al., 1996; Litvan, 
Mangone, et al., 1996). There are conflicting reports 
whether males or females are more likely to develop 
PSP (Bower, Maraganore, McDonnell, & Roca, 1997; 
Golbe, 1996). Overall prevalence is estimated between 
1.4 and 6.4 per 100,000 (Golbe, Davis, Schoenberg, & 
Duvoisin, 1988; Schrag, Ben-Shlomo, & Quinn, 1999). 
NEUROPATHOLOGY /PATHOPHYSIOLOGY 
The pathophysiology of PSP involves severe neuronal 
degeneration of subcortical structures and minimal 
cortical lesions. Lesion sites are somewhat variable 
and typically occur between the upper brainstem 
and basal ganglia. Broadly, there is evidence of neu-
ronal loss in the striatum and substantia nigra, and 
degeneration of structures in the basal ganglia, 
upper brainstem, and cerebellum (Agid, Ruberg, 
DuBois, & Pillon, 1987). Lesions may compromise 
the nigrostriatal pathway, basal forebrain, pedunculo-
pontine nucleus, subnucleus compactus, mesencepha-
lopontine tegmental nuclei, and locus ceruleus 
(Grafman, Litvan, & Stark, 1995). Dopamine levels 
drop drastically during the course of the illness 
leading to parkinsonian-type symptoms. 
Degeneration impacts ascending pathways from 
subcortical structures to the prefrontal cortex. Graf-
man et al. (1995) hypothesized that pathology in the 
dorsolateral frontal, lateral-orbitofrontal, and anterior 
cingulate circuits contributes to specific cognitive 
dysfunctions (executive functioning, social-cognitive, 
and attention). 
Although frontal lobe pathology is not promi-
nent, multiple positron emission tomography (PET) 
studies have revealed frontal hypometabolism 
(Bhatt, Snow, Martin, Peppard, & Caine, 1991; Blin 
et al., 1990; Blin et al., 1992), and some imaging studies 
have reported significant frontal cortical atrophy 
(Cordato, Halliday, Harding, Hely, & Morris, 2000; 
Cordato et al., 2002; Groschel et al., 2004). MRI studies 
have found atrophy of midbrain structures most pro-
nounced in the superior colliculi and pons (Masucci, 
Borts, Smimiotopoulos, Kurtzke, & Schellinger, 1985; 
Schonfeld, Globe, Sage, Safer, & Duvoisin, 1987). 
NEUROPSYCHOLOGICAL/ CLINICAL 
PRESENTATION 
Consistent with subcortical dysfunction, common 
manifestations of PSP reflect executive dysfunction, 
including cognitive slowing, impaired set-shifting, 
and decreased verbal fluency (Grafman et al., 1995; 
Jacobs, Levy, & Marder, 2003). It is generally believed 
that these deficits are related to frontal deafferentation 
secondary to subclinical lesions, although some 
researchers have hypothesized a more direct relation-
ship between frontal lobe pathology and behavioral 
deficits (Cordato et al., 2002). Immediate and delayed 
recall of information can vary from normal to 
impaired, whereas recognition memory is improved 
or intact (Jacobs et al., 2003). Primary language 
abilities are typically preserved, though word-finding 
problems may develop years following formal 
diagnosis (Lezak, Howieson, & Loring, 2004). Not 
surprisingly given ocular involvement, visuospatial 
skills are often impaired. Visual attention impairment 
is typically related to duration of PSP (Kertzman, 
Robinson, & Litvan, 1990). 
The course of physical symptoms consists of 
postural instability and falls several years prior to 
formal diagnosis. The hallmark physical symptom 
of PSP is a vertical gaze palsy that typically occurs 
relatively late in the disease process. Compensation 
for visual limitations can frequently lead to falls. 
Bradykinesia, rigidity, impaired control of mouth/ 
neck are also relatively common later in the course. 
It is notable that the development of core symptoms 
may present late, or never develop, during the 
course of the disease (Litvan et al., 2003). For example, 
histological confirmed cases of PSP have been 
reported without ophthalmoplegia (Santacruz, Uttl, 
Litvan, & Grafman, 1998). Respiratory arrest may 
occur due to a degenerative process involving the 
brainstem respiratory centers, or be secondary to 
pneumonia. Unlike Parkinson's disease, patients 
with PSP tend to have more of an erect rather than a 
stooped posture and lack tremor (Rapper & Brown, 
2005). 
Consistent with executive dysfunction, two of 
the most common behavioral manifestations of PSP 
are apathy and disinhibition. One study administered 
the Neuropsychiatric Inventory to 22 patients with PSP 
and found apathy to be the most prevalent 
neuropsychiatric feature, present in 91% of patients 
(Litvan, Mega, Cummings, & Fairbanks, 1996). Disin-
hibition was exhibited by one-third of patients, 
followed by dysphoria (18%) and anxiety (18%). 
Impaired metacognitive awareness has also been 
observed and is attributed to the disruption of 
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frontostriatal feedback loops (O'Keeffe et al., 2007). 
Obsessive behaviors, euphoria, and depressive 
symptoms are also possible (Destee et al., 1990). 
Sleep abnormalities are prevalent as well and are 
most often characterized by shortened total sleep 
time, frequent awakenings, and decreased REM sleep 
(Cummings, 2003). 
DIAGNOSIS 
Although multiple diagnostic criteria have been 
proposed (e.g., Collins, Ahlskog, Parisi, & Maraga-
nore, 1995; Tolosa, Valldeoriola, & Marti, 1994), 
those set forth by Litvan et al. (1996) are the most 
frequently cited in the literature and form the basis 
for the National Institute of Neurological Disorders 
and Stroke and Society for Progressive Supranuclear 
Palsy (NINDS-SPSP; Litvan et al., 2003) clinical crite-
ria. Diagnosis of "possible PSP" requires either 
vertical supranuclear palsy or both slowing of vertical 
saccades and postural instability with falls during the 
1st year of disease onset. "Probable" diagnosis of PSP 
requires vertical supranuclear palsy and prominent 
postural instability with falls within the 1st year of 
disease onset. Diagnosis of possible or probable PSP 
requires symptom onset at or after age 40, and it is 
necessary that there be a gradual progression of symp-
toms. "Definite" diagnosis of possible or probable PSP 
requires histopathologic confirmation at autopsy. 
NINDS-SPSP clinical criteria provide a number of 
supportive criteria to assist in differential diagnosis. 
Supportive motor features include symmetric akinesia 
or rigidity (proximal greater than distal) and neck dys-
tonia. An early onset of two or more of the following 
cognitive symptoms is also supportive of PSP diagno-
sis: impaired abstraction, decreased verbal fluency, 
"utilization or imitation behavior," "frontal release" 
signs, and apathy. In addition, PSP may be considered 
if motor symptoms do not respond, or minimally 
respond, to levodopa therapy and if there are early 
symptoms of dysphagia or dysarthria. 
PSP is often misdiagnosed early in the course of 
the disease as Parkinson's disease or confused with 
other parkinsonian disorders. Severity and pattern 
of executive deficits characterized by slowed informa-
tion processing, impaired accuracy in carrying out 
plans, and difficulty in set shifting tends to differenti-
ate PSP patients from others with basal ganglia lesions 
(Robbins et al., 1994). The combination of postural 
instability leading to falls early in the course of the 
disease and vertical gaze palsy are also key symptoms 
in differentiating PSP from other disorders with 
parkinsonism and dementia. 
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Neuroimaging techniques can be useful in 
differential diagnosis. Diffusion-weighted imaging 
has shown promise in differentiating PSP from Par-
kinson's disease early in disease onset based on 
increased regional apparent diffusion coefficients in 
the putamen, globus pallidus, and caudate nucleus 
(Seppi et al., 2003). An additional reliable manner to 
differentiate PSP from Parkinson's disease is signifi-
cantly lower anteroposterior diameter of the midbrain 
on axial T2-weighted magnetic resonance images 
(Warmuth-Metz, Naumann, Csoti, & Solymosi, 2001). 
Differential diagnosis between PSP and corticoba-
sal degenerative syndrome (CBDS) is challenging. 
These conditions have numerous factors in common 
including similar neuropsychological profiles (Pillon 
et al., 1995), pathological features (Feany, Mattiace, & 
Dickson, 1996), and the finding that both conditions 
are considered to be predominantly 4-repeat tauopa-
thies (Kertesz & Munoz, 2004). Further complicating 
the differential diagnosis, individuals with CBDS may 
exhibit vertical gaze palsy, falls, and symmetrical 
extrapyramidal syndrome (Litvan, Goetz, & Lang, 
2000). One possible distinguishing feature between 
these syndromes is greater atrophy of the midbrain, 
pons, thalamus, and striatum in PSP relative to CBDS 
(Boxer et al., 2006). 
TREATMENT 
Unfortunately, PSP is a treatment-resistant and degen-
erative condition. Although dopaminergic agents 
can improve the parkinsonian features, they can 
also induce adverse side effects, such as orthostatic 
hypotension, hallucinations/ delusions, and gastroin-
testinal complaints (Kompoliti, Goetz, Litvan, 
Jellinger, & Vemy, 1998). It is recommended that 
anticholinergic agents be avoided (Cummings, 
2003). There is no significant improvement with leva-
dopa therapy. 
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Pseudotumor cerebri represents a syndrome that is 
characterized by persisting headache and papille-
dema (unilateral or bilateral) in the absence of focal 
neurologic signs, abnormal CSF composition, and 
enlarged ventricles or an intracranial mass. The pre-
sentation is associated with increased intracranial 
hypertension, most commonly idiopathic in nature. 
Pseudotumor cerebri is most frequently observed 
in overweight young women with a relative 
